The Oncologist, Vol. 11, No. 4, 397-408, April 2006; doi:10.1634/theoncologist.11-4-397 © 2006 AlphaMed Press
TNF-
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
S. Radfar, Y. Wang, and H. T. Khong Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo J. Immunol., November 15, 2009; 183(10): 6800 - 6807. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhang, H. Y. Wang, G. Bhutani, X. Liu, M. Paessler, J. W. Tobias, D. Baldwin, K. Swaminathan, M. C. Milone, and M. A. Wasik Lack of TNF{alpha} expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis PNAS, September 15, 2009; 106(37): 15843 - 15848. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Warren, S. F. Shoemaker, D. J. Shealy, W. Bshar, and M. M. Ip Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice Mol. Cancer Ther., September 1, 2009; 8(9): 2655 - 2663. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yuan, X. Lin, G. Manorek, I. Kanatani, L. H. Cheung, M. G. Rosenblum, and S. B. Howell Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors Mol. Cancer Ther., July 1, 2009; 8(7): 1906 - 1915. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Duffy, E. McKiernan, N. O'Donovan, and P. M. McGowan Role of ADAMs in Cancer Formation and Progression Clin. Cancer Res., February 15, 2009; 15(4): 1140 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jiang, R. Goel, M. A. Iftekhar, R. Visaria, J. D. Belcher, G. M. Vercellotti, and J. C. Bischof Tumor necrosis factor-{alpha}-induced accentuation in cryoinjury: mechanisms in vitro and in vivo Mol. Cancer Ther., August 1, 2008; 7(8): 2547 - 2555. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Crippa, A. Gasparri, A. Sacchi, E. Ferrero, F. Curnis, and A. Corti Synergistic Damage of Tumor Vessels with Ultra Low-Dose Endothelial-Monocyte Activating Polypeptide-II and Neovasculature-Targeted Tumor Necrosis Factor-{alpha} Cancer Res., February 15, 2008; 68(4): 1154 - 1161. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Hohenberger and W. M. Wysocki Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose? Oncologist, February 1, 2008; 13(2): 175 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Goel, D. Swanlund, J. Coad, G. F. Paciotti, and J. C. Bischof TNF-{alpha}-based accentuation in cryoinjury--dose, delivery, and response Mol. Cancer Ther., July 1, 2007; 6(7): 2039 - 2047. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mena, M. Benlloch, A. Ortega, J. Carretero, E. Obrador, M. Asensi, I. Petschen, B. D. Brown, and J. M. Estrela Bcl-2 and Glutathione Depletion Sensitizes B16 Melanoma to Combination Therapy and Eliminates Metastatic Disease Clin. Cancer Res., May 1, 2007; 13(9): 2658 - 2666. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Lejeune and A. M.M. Eggermont Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor Is a Useful Therapy for Advanced Melanoma of the Limbs J. Clin. Oncol., April 10, 2007; 25(11): 1449 - 1450. [Full Text] [PDF] |
||||
![]() |
J. W. Barrett, J. Sypula, F. Wang, L. R. Alston, Z. Shao, X. Gao, T. S. Irvine, and G. McFadden M135R Is a Novel Cell Surface Virulence Factor of Myxoma Virus J. Virol., January 1, 2007; 81(1): 106 - 114. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |